Literature DB >> 12376341

Content-dependent activity of lung surfactant protein B in mixtures with lipids.

Z Wang1, J E Baatz, B A Holm, R H Notter.   

Abstract

The content-dependent activity of surfactant protein (SP)-B was studied in mixtures with dipalmitoyl phosphatidylcholine (DPPC), synthetic lipids (SL), and purified phospholipids (PPL) from calf lung surfactant extract (CLSE). At fixed SP-B content, adsorption and dynamic surface tension lowering were ordered as PPL/SP-B approximately SL/SP-B > DPPC/SP-B. All mixtures were similar in having increased surface activity as SP-B content was incrementally raised from 0.05 to 0.75% by weight. SP-B had small but measurable effects on interfacial properties even at very low levels < or =0.1% by weight. PPL/SP-B (0.75%) had the highest adsorption and dynamic surface activity, approaching the behavior of CLSE. All mixtures containing 0.75% SP-B reached minimum surface tensions <1 mN/m in pulsating bubble studies at low phospholipid concentration (1 mg/ml). Mixtures of PPL or SL with SP-B (0.5%) also had minimum surface tensions <1 mN/m at 1 mg/ml, whereas DPPC/SP-B (0.5%) reached <1 mN/m at 2.5 mg/ml. Physiological activity also was strongly dependent on SP-B content. The ability of instilled SL/SP-B mixtures to improve surfactant-deficient pressure-volume mechanics in excised lavaged rat lungs increased as SP-B content was raised from 0.1 to 0.75% by weight. This study emphasizes the crucial functional activity of SP-B in lung surfactants. Significant differences in SP-B content between exogenous surfactants used to treat respiratory disease could be associated with substantial activity variations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376341     DOI: 10.1152/ajplung.00431.2001

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  9 in total

1.  A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema.

Authors:  Frank Guarnieri; Jean L Spencer; Edgar C Lucey; Matthew A Nugent; Phillip J Stone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS.

Authors:  Marla R Wolfson; Jichuan Wu; Terrence L Hubert; Timothy J Gregory; Jan Mazela; Thomas H Shaffer
Journal:  Pediatr Res       Date:  2012-07-20       Impact factor: 3.756

Review 3.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 4.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 5.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

6.  Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.

Authors:  Zhengdong Wang; Yusuo Chang; Adrian L Schwan; Robert H Notter
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-07       Impact factor: 6.914

7.  Synthetic lung surfactants containing SP-B and SP-C peptides plus novel phospholipase-resistant lipids or glycerophospholipids.

Authors:  Robert H Notter; Rohun Gupta; Adrian L Schwan; Zhengdong Wang; Mohanad Gh Shkoor; Frans J Walther
Journal:  PeerJ       Date:  2016-10-27       Impact factor: 2.984

8.  The role of surfactant in respiratory distress syndrome.

Authors:  Christopher Cheng-Hwa Ma; Sze Ma
Journal:  Open Respir Med J       Date:  2012-07-13

9.  Activity and biophysical inhibition resistance of a novel synthetic lung surfactant containing Super-Mini-B DATK peptide.

Authors:  Robert H Notter; Zhengdong Wang; Frans J Walther
Journal:  PeerJ       Date:  2016-01-05       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.